CN104383097A - Traditional Chinese medicine for treating lupus erythematosus - Google Patents
Traditional Chinese medicine for treating lupus erythematosus Download PDFInfo
- Publication number
- CN104383097A CN104383097A CN201410705094.2A CN201410705094A CN104383097A CN 104383097 A CN104383097 A CN 104383097A CN 201410705094 A CN201410705094 A CN 201410705094A CN 104383097 A CN104383097 A CN 104383097A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- lupus erythematosus
- raw
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating lupus erythematosus. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-18 parts of white paeony root, 20-30 parts of radix rehmanniae preparata, 20-30 parts of astragalus membranaceus, 15-25 parts of cassia bark, 20-30 parts of largetrifoliolious bugbane rhizome, 25-35 parts of Chinese thorowax root, 10-20 parts of safflower, 12-18 parts of donkey-hide glue, 10-16 parts of raw oyster shell, 10-16 parts of raw turtle shell, 8-15 parts of raw tortoise plastron and 6-10 parts of white mulberry root-bark. The traditional Chinese medicine for treating lupus erythematosus, disclosed by the invention, adopts Chinese thorowax root as a main medicament, other auxiliary medicaments are matched, and the main medicament and the auxiliary medicaments act upon each other and have synergistic effects, so that the traditional Chinese medicine can play good roles in conditioning and tonifying the five internal organs, reinforcing qi and nourishing blood, soothing the liver and regulating qi circulation, and improving immunity, has a very good curative effect on lupus erythematosus, and is simple in raw material and convenient to take.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine for the treatment of lupus erythematosus.
Background technology
Lupus erythematosus (LE) is that a kind of typical autoimmune connective tissue is sick, is more common in 15 ~ 40 years old women.Lupus erythematosus is a kind of disease spectrality disease, can be divided into the hypotypes such as discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), systemic lupus erythematosus (sle) (SLE), lupus erythematosus profundus (LEP), neonatal lupus erythematosus (NLE), Drug lupus erythematosus (DIL).The medicine of current treatment lupus erythematosus is numerous, such as publication number is: CN103920071A, name is called the Chinese invention patent application of " a kind of Chinese medicine composition for the treatment of subacute cutaneous lupus erythematosus ", disclose a kind of Chinese medicine composition for the treatment of subacute cutaneous lupus erythematosus, every agent medicine is made up of the crude drug of following weight: Cornu Bubali 14-16g, Radix Rehmanniae 10-12g, Radix Paeoniae Rubra 10-12g, Flos Campsis 8-12g, Radix Arnebiae (Radix Lithospermi) 8-12g, Radix Angelicae Dahuricae 8-13g, Nidus Vespae 10-13g, Bombyx Batryticatus(processed) 10-14g, Ramulus Euonymi 10-13g, Radix Polygoni Multiflori 10-15g, roach sloughs off 5-7g, Cortex Moutan 10-12g, Radix Saposhnikoviae 10-12g, Radix Gentianae Macrophyllae 10-13g, Rhizoma Smilacis Chinensis 10-14g, Herba Pyrolae 2-4g, Folium Cucumidis sativi 1-3g, Chinese medicine composition of the present invention can improve the body autoimmune function of people, the cell of activating human body, detoxifying function in purged body, have no side effect, evident in efficacy, heat-clearing and toxic substances removing, cooling blood and dissolving stasis, spleen invigorating removing food stagnancy, treating both the principal and secondary aspects of a disease, rapid speckle dispelling.But its compatibility is comparatively complicated.
Summary of the invention
The technical problem to be solved in the present invention is to provide the Chinese medicine of comparatively simple, safe and reliable, the eutherapeutic treatment lupus erythematosus of a kind of compatibility.
For solving the problems of the technologies described above, the present invention by the following technical solutions:
The present invention treats the Chinese medicine of lupus erythematosus, is to be made up of the raw material of following weight proportioning:
The Radix Paeoniae Alba 10 ~ 18, Radix Rehmanniae Preparata 20 ~ 30, the Radix Astragali 20 ~ 30, Cortex Cinnamomi 15 ~ 25, Rhizoma Cimicifugae 20 ~ 30, Radix Bupleuri 25 ~ 35, Flos Carthami 10 ~ 20, Colla Corii Asini 12 ~ 18, Concha Ostreae 10 ~ 16, raw Carapax Trionycis 10 ~ 16, raw tortoise plastron 8 ~ 15, Cortex Mori 6 ~ 10.
The preferred weight proportioning of each raw material is:
The Radix Paeoniae Alba 12 ~ 16, Radix Rehmanniae Preparata 22 ~ 28, the Radix Astragali 22 ~ 28, Cortex Cinnamomi 18 ~ 22, Rhizoma Cimicifugae 22 ~ 28, Radix Bupleuri 28 ~ 32, Flos Carthami 12 ~ 18, Colla Corii Asini 13 ~ 17, Concha Ostreae 12 ~ 15, raw Carapax Trionycis 12 ~ 15, raw tortoise plastron 9 ~ 13, Cortex Mori 7 ~ 9.
The optimum weight proportioning of each raw material is:
The Radix Paeoniae Alba 14, Radix Rehmanniae Preparata 25, the Radix Astragali 25, Cortex Cinnamomi 20, Rhizoma Cimicifugae 25, Radix Bupleuri 30, Flos Carthami 15, Colla Corii Asini 14, Concha Ostreae 13, raw Carapax Trionycis 13, raw tortoise plastron 11, Cortex Mori 8.
The preparation method that the present invention treats the Chinese medicine of lupus erythematosus is: take the raw material Radix Paeoniae Alba, Radix Rehmanniae Preparata, the Radix Astragali, Cortex Cinnamomi, Rhizoma Cimicifugae, Radix Bupleuri, Flos Carthami, Colla Corii Asini, Concha Ostreae, raw Carapax Trionycis, raw tortoise plastron, Cortex Mori by weight ratio, add the soak by water of 5 ~ 8 times of raw material weights, after water boils, slow fire boils 30 ~ 40 minutes, leach medicinal liquid, to obtain final product.
The instructions of taking that the present invention treats the Chinese medicine of lupus erythematosus is: oral, and every day 2 times, each serving 200 ~ 250 grams.
The Chinese medicine that the present invention treats lupus erythematosus take Radix Bupleuri as principal agent, to arrange in pairs or groups other accessory drugs, they influence each other, synergism, thus play well adjust tonifying five ZANG-organs, benefiting QI and nourishing blood, unclog and readjust irritability and improve immunity, have good curative effect to lupus erythematosus, and its raw material is simple, taking convenience.
Detailed description of the invention
With embodiment, the invention will be further described below, but the present invention is not limited to these embodiments.
Number described in following embodiment is weight portion.
Embodiment 1
Drug weight proportioning:
The Radix Paeoniae Alba 10 parts, 20 parts, Radix Rehmanniae Preparata, the Radix Astragali 20 parts, Cortex Cinnamomi 15 parts, Rhizoma Cimicifugae 20 parts, Radix Bupleuri 25 parts, 10 parts, Flos Carthami, 12 parts, Colla Corii Asini, Concha Ostreae 10 parts, raw Carapax Trionycis 10 parts, raw tortoise plastron 8 parts, Cortex Mori 6 parts.
Preparation method:
Take raw material by above-mentioned weight proportion, add the soak by water of 5 times of raw material weights, after water boils, slow fire boils 30 minutes, leaches medicinal liquid, to obtain final product.
Embodiment 2
Drug weight proportioning:
The Radix Paeoniae Alba 18 parts, 30 parts, Radix Rehmanniae Preparata, the Radix Astragali 30 parts, Cortex Cinnamomi 25 parts, Rhizoma Cimicifugae 30 parts, Radix Bupleuri 35 parts, 20 parts, Flos Carthami, 18 parts, Colla Corii Asini, Concha Ostreae 16 parts, raw Carapax Trionycis 16 parts, raw tortoise plastron 15 parts, Cortex Mori 10 parts.
Preparation method:
Take raw material by above-mentioned weight proportion, add the soak by water of 8 times of raw material weights, after water boils, slow fire boils 40 minutes, leaches medicinal liquid, to obtain final product.
Embodiment 3
Drug weight proportioning:
The Radix Paeoniae Alba 14 parts, 25 parts, Radix Rehmanniae Preparata, the Radix Astragali 25 parts, Cortex Cinnamomi 20 parts, Rhizoma Cimicifugae 25 parts, Radix Bupleuri 30 parts, 15 parts, Flos Carthami, 14 parts, Colla Corii Asini, Concha Ostreae 13 parts, raw Carapax Trionycis 13 parts, raw tortoise plastron 11 parts, Cortex Mori 8 parts.
Preparation method:
Take raw material by above-mentioned weight proportion, add the soak by water of 6 times of raw material weights, after water boils, slow fire boils 35 minutes, leaches medicinal liquid, to obtain final product.
Experimental example:
The beneficial effect that the present invention treats the Chinese medicine of lupus erythematosus is set forth further below by way of experimental example.
1, Subject Population:
Be divided into A, B two experimental grouies:
A group: female patient 100 example; 15 ~ 25 years old age.
B group: female patient 150 example; 25 ~ 40 years old age.
2, drug administration method:
Chinese medicine every day of the treatment lupus erythematosus that the oral embodiment of the present invention 3 is obtained 2 times, each serving 250 grams, serve on 30 days.
3, efficacy evaluation:
(1) invalid: compared with before taking medicine, therapeutic effect is not obvious.
(2) effective: therapeutic effect is obvious.
4, therapeutic effect:
Claims (3)
1. treat a Chinese medicine for lupus erythematosus, it is characterized in that being made up of the raw material of following weight proportioning:
The Radix Paeoniae Alba 10 ~ 18, Radix Rehmanniae Preparata 20 ~ 30, the Radix Astragali 20 ~ 30, Cortex Cinnamomi 15 ~ 25, Rhizoma Cimicifugae 20 ~ 30, Radix Bupleuri 25 ~ 35, Flos Carthami 10 ~ 20, Colla Corii Asini 12 ~ 18, Concha Ostreae 10 ~ 16, raw Carapax Trionycis 10 ~ 16, raw tortoise plastron 8 ~ 15, Cortex Mori 6 ~ 10.
2. the Chinese medicine for the treatment of lupus erythematosus according to claim 1, is characterized in that the weight proportion of each raw material is:
The Radix Paeoniae Alba 12 ~ 16, Radix Rehmanniae Preparata 22 ~ 28, the Radix Astragali 22 ~ 28, Cortex Cinnamomi 18 ~ 22, Rhizoma Cimicifugae 22 ~ 28, Radix Bupleuri 28 ~ 32, Flos Carthami 12 ~ 18, Colla Corii Asini 13 ~ 17, Concha Ostreae 12 ~ 15, raw Carapax Trionycis 12 ~ 15, raw tortoise plastron 9 ~ 13, Cortex Mori 7 ~ 9.
3. the Chinese medicine for the treatment of lupus erythematosus according to claim 2, is characterized in that the weight proportion of each raw material is:
The Radix Paeoniae Alba 14, Radix Rehmanniae Preparata 25, the Radix Astragali 25, Cortex Cinnamomi 20, Rhizoma Cimicifugae 25, Radix Bupleuri 30, Flos Carthami 15, Colla Corii Asini 14, Concha Ostreae 13, raw Carapax Trionycis 13, raw tortoise plastron 11, Cortex Mori 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410705094.2A CN104383097A (en) | 2014-11-27 | 2014-11-27 | Traditional Chinese medicine for treating lupus erythematosus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410705094.2A CN104383097A (en) | 2014-11-27 | 2014-11-27 | Traditional Chinese medicine for treating lupus erythematosus |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104383097A true CN104383097A (en) | 2015-03-04 |
Family
ID=52601121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410705094.2A Pending CN104383097A (en) | 2014-11-27 | 2014-11-27 | Traditional Chinese medicine for treating lupus erythematosus |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104383097A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840714A (en) * | 2015-05-29 | 2015-08-19 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating lupus erythematosus |
CN105963294A (en) * | 2016-06-18 | 2016-09-28 | 张阳康 | Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156051A (en) * | 1996-09-20 | 1997-08-06 | 杨郭明 | Immunological powdered Chiense drug |
CN1175451A (en) * | 1997-07-20 | 1998-03-11 | 迟经惠 | Plaster for lupus erythematosus |
CN102228619A (en) * | 2011-05-31 | 2011-11-02 | 王莲芬 | Chinese patent medicine for treating systemic lupus erythematosus |
-
2014
- 2014-11-27 CN CN201410705094.2A patent/CN104383097A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156051A (en) * | 1996-09-20 | 1997-08-06 | 杨郭明 | Immunological powdered Chiense drug |
CN1175451A (en) * | 1997-07-20 | 1998-03-11 | 迟经惠 | Plaster for lupus erythematosus |
CN102228619A (en) * | 2011-05-31 | 2011-11-02 | 王莲芬 | Chinese patent medicine for treating systemic lupus erythematosus |
Non-Patent Citations (1)
Title |
---|
王文生等: "王俊志***经验", 《实用中医药杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840714A (en) * | 2015-05-29 | 2015-08-19 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating lupus erythematosus |
CN105963294A (en) * | 2016-06-18 | 2016-09-28 | 张阳康 | Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101766773A (en) | Traditional Chinese medicine formula for treating heel pain | |
CN102512617B (en) | Chinese herbal preparation for treating psoriasis | |
CN104147447A (en) | Traditional Chinese medicine for treating pulmonary emphysema | |
CN103735790A (en) | Traditional Chinese medicine composition for treating tinnitus | |
CN103495019B (en) | A kind of tranquilizing by nourishing the heart Chinese medicine preparation and preparation method thereof | |
CN103550697A (en) | Traditional Chinese medicine for treating hysteromyoma | |
CN103356969A (en) | Traditional Chinese medicine composition for treating hysteromyoma | |
CN106266896A (en) | A kind of invigorating primordial QI, kidney invigorating and YANG supporting, bone and muscle strengthening, the pill of curing rheumatism | |
CN104383097A (en) | Traditional Chinese medicine for treating lupus erythematosus | |
CN103721082B (en) | A kind of Chinese medicine composition of cure scapulohumeral periarthritis | |
CN100381155C (en) | Medicine for treating mammary glands hyperplasia | |
CN102366601A (en) | Traditional Chinese medicine preparation for treating apoplexia, facial paralysis and hemiplegia | |
CN103845620A (en) | Traditional Chinese medicine for treating raynaud disease | |
CN104138572A (en) | Medicine used for treating chloasma | |
CN103705855A (en) | Traditional Chinese medicine for treating thyroiditis | |
CN103550679A (en) | Traditional Chinese medicine formula for treatment of lithangiuria | |
CN105853930A (en) | Traditional Chinese medicine composition for treating depression | |
CN104042739A (en) | Traditional Chinese medicine for treating prospermia | |
CN104800799A (en) | Traditional Chinese medicament for treating endometrial thickening with ovarian cysts | |
CN104189227A (en) | Traditional Chinese medicine used for treating rosacea | |
CN110787237B (en) | Traditional Chinese medicine composition for effectively treating gastrocnemius spasm and preparation method and application thereof | |
CN104984170A (en) | Application of traditional Chinese medicine composite in treating rabies | |
CN104258107A (en) | Traditional Chinese medicine for treating postartum convulsion | |
CN104189132A (en) | Traditional Chinese medicine used for treating sexual intercourse in dream | |
CN104189354A (en) | Traditional Chinese medicine used for treating leucorrhea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150304 |
|
WD01 | Invention patent application deemed withdrawn after publication |